PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18671950-1	2008	The glycolipid alpha-galactosylceramide (alpha-GalCer), when presented on CD1 molecules by antigen presenting cells (APCs) to invariant NKT (iNKT cells), is a potent immunomodulator.	alpha-galactosylceramide	15-39	CD1c molecule	Homo sapiens	74-77	
21575695-2	2012	The high-affinity CD1d antigen alpha-galactosylceramide analogue KRN7000 (KRN) activates a cascade of anti-tumor effector cells and clinical studies have already had some initial success.	alpha-galactosylceramide	31-55	CD1c molecule	Homo sapiens	18-21	
23885215-4	2013	We demonstrate here that CD1c, which is co-expressed with CD1d on blood dendritic cells and on a fraction of B cells, is able to present alpha-galactosylceramide (alpha-GalCer) as a weak agonist to human iNKT cells, and that the presence of CD1c synergistically enhances alpha-GalCerdependent activation of iNKT cells by CD1d.	alpha-galactosylceramide	137-161	CD1c molecule	Homo sapiens	25-29	
23885215-4	2013	We demonstrate here that CD1c, which is co-expressed with CD1d on blood dendritic cells and on a fraction of B cells, is able to present alpha-galactosylceramide (alpha-GalCer) as a weak agonist to human iNKT cells, and that the presence of CD1c synergistically enhances alpha-GalCerdependent activation of iNKT cells by CD1d.	alpha-galactosylceramide	137-161	CD1c molecule	Homo sapiens	241-245	
18671950-1	2008	The glycolipid alpha-galactosylceramide (alpha-GalCer), when presented on CD1 molecules by antigen presenting cells (APCs) to invariant NKT (iNKT cells), is a potent immunomodulator.	alpha-galactosylceramide	41-53	CD1c molecule	Homo sapiens	74-77	
18006319-3	2008	Among the several (glyco)lipids identified to cause T-cell stimulation in complex with CD1, alpha-galactosyl ceramide (alpha-GalCer) is one of the most well studied.	alpha-galactosylceramide	92-117	CD1c molecule	Homo sapiens	87-90	
12360465-3	2002	METHODS: We used a human CD1d (hCD1d) tetramer produced by a baculovirus expressing recombinant CD1d protein complexed with alpha-galactosylceramide (alpha-GalCer) and quantitated hCD1d tetramer reactive cells in blood and liver from controls and patients with primary biliary cirrhosis (PBC).	alpha-galactosylceramide	124-148	CD1c molecule	Homo sapiens	31-35	
17071611-6	2006	Nor were any required for the CD1d molecule to bind and present alpha-galactosyl ceramide after lysosomal processing of a precursor lipid, galactosyl-(alpha1-2)-galactosyl ceramide.	alpha-galactosylceramide	64-89	CD1c molecule	Homo sapiens	30-33	
12076157-1	2002	Alpha-galactosyl ceramide has been identified to be a potent stimulatory agent for a novel immunological process, mediated by CD1 molecules.	alpha-galactosylceramide	0-25	CD1c molecule	Homo sapiens	126-129	
26107189-0	2015	Influence of Endosomal Escape and Degradation of alpha-Galactosylceramide Loaded Liposomes on CD1d Antigen Presentation.	alpha-galactosylceramide	49-73	CD1c molecule	Homo sapiens	94-97	
28104514-3	2017	We have developed an approach of in vivo expansion of Tregs with RGI-2001, a novel liposomal formulation of a synthetic derivative of alpha-galactosylceramide, a naturally occurring ligand that binds to CD1 and activates and expands invariant natural killer cells.	alpha-galactosylceramide	134-158	CD1c molecule	Homo sapiens	203-206	
11970881-2	2002	Classical NKT cells display TCRs of restricted heterogeneity (Valpha14-Jalpha281) and recognize lipid antigens (e.g., alpha-galactosyl ceramide) presented by nonpolymorphic CD1 molecules.	alpha-galactosylceramide	118-143	CD1c molecule	Homo sapiens	173-176	
9782129-4	1998	Mouse or human CD1 molecules can present the glycolipid alpha-galactosylceramide (alpha-GalCer) to NK T cells from either species.	alpha-galactosylceramide	56-80	CD1c molecule	Homo sapiens	15-18	
9782129-4	1998	Mouse or human CD1 molecules can present the glycolipid alpha-galactosylceramide (alpha-GalCer) to NK T cells from either species.	alpha-galactosylceramide	82-94	CD1c molecule	Homo sapiens	15-18	
25248321-8	2015	Furthermore, RA and/or CD38 ligation increased splenocyte proliferation and differentiation after treatment with the CD1 ligand alpha-galactosylceramide (alphaGalCer), evidenced by an increase in the number of splenic dendritic cells, NKT cells, and germinal center plasmacytes.	alpha-galactosylceramide	128-152	CD1c molecule	Homo sapiens	117-120